BioSpace News Archive

Rapid advancements in the neuroprosthetic technology, rising number of clinical trials for effective management of ABIs, and technological advancements in hearing devices are some key factors expected to drive market growth.

Rising geriatric population, growing prevalence of neurological disorders such as Parkinson’s disease, epilepsy, and dystonia, and continuous advancements in neurosurgical technologies are among the key factors expected to drive market revenue growth.

Growing geriatric population worldwide, rising cases of oral disorders, and increasing demand for advanced dental imaging solutions are among the key factors expected to drive market revenue growth during the forecast period.

Rising investments in proteomics, increasing public awareness about protein expression as critical clinical tool, and availability of favorable reimbursement facilities are some key factors expected to drive market growth.

The investment, under the Federal Funding Programme for COVID-19 Medicines initiative, will enable the acceleration of the clinical development of ambrisentan.

AstraZeneca and Amgen’s TEZSPIRE (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

InMed Pharmaceuticals Inc., a leader in the development, manufacturing and commercialization of rare cannabinoids, confirmed that, at its annual general meeting of shareholders held on December 17, 2021, all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 28, 2021, were approved by the shareholders.

Ipsen and GENFIT, have entered into a long-term strategic partnership for global collaboration between the two companies.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that it will attend the following upcoming virtual investor conferences.

A biomechanical evaluation of the novel LinQ device revealed statistically significant fixation of the sacroiliac (SI) joint. Developed by Tampa -based medical device company, PainTEQ , the LinQ SI Joint Stabilization System is a minimally invasive procedure in which a surgeon inserts a small, single patented implant into the SI joint.